RT Journal Article
SR Electronic
T1 Haplotype networks of SARS-CoV-2 infections in the Diamond Princess cruise ship outbreak
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.23.20041970
DO 10.1101/2020.03.23.20041970
A1 Sekizuka, Tsuyoshi
A1 Itokawa, Kentaro
A1 Kageyama, Tsutomu
A1 Saito, Shinji
A1 Takayama, Ikuyo
A1 Asanuma, Hideki
A1 Nao, Naganori
A1 Tanaka, Rina
A1 Hashino, Masanori
A1 Takahashi, Takuri
A1 Kamiya, Hajime
A1 Yamagishi, Takuya
A1 Kakimoto, Kensaku
A1 Suzuki, Motoi
A1 Hasegawa, Hideki
A1 Wakita, Takaji
A1 Kuroda, Makoto
YR 2020
UL http://medrxiv.org/content/early/2020/03/27/2020.03.23.20041970.abstract
AB The Diamond Princess (DP) cruise ship was put under quarantine offshore Yokohama, Japan, after a passenger who disembarked in Hong Kong was confirmed as a COVID-19 case. We performed whole genome sequencing of SARS-CoV-2 directly from PCR-positive clinical specimens and conducted a haplotype network analysis of the outbreak. All tested isolates exhibited a transversion at G11083T, suggesting that SARS-CoV-2 dissemination on the DP originated from a single introduction event before the quarantine started. Although further spreading might have been prevented by quarantine, some progeny clusters were linked to transmission through mass-gathering events in the recreational areas and direct transmission among passengers who shared cabins during the quarantine. This study demonstrates the usefulness of haplotype network analysis in identifying potential infection routes.One Sentence Summary Genome-based tracing of SARS-CoV-2 infections among passengers and crews in Diamond Princess cruise ship during the quarantineCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialThis study is not a clinical trial, but genome surveillance of SARS-CoV-2.Funding StatementThis study was supported by a Grant-in Aid from the Japan Agency for Medical Research and Development (AMED) under Grant Numbers JPfk0108103.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe new sequences have been deposited in GISAID with accession IDs EPI_ISL_416565 – EPI_ISL_416634. UPDATE 23/3/20